Antidepressant Long-Term Efficacy Pre-Approval Will Be Voted On By Cmte.
Executive Summary
FDA will ask whether it is reasonable to require both acute and long-term efficacy data in applications for antidepressants and other chronic psychiatric drugs at its Psychopharmacologic Drugs Advisory Committee meeting on Oct. 25
You may also be interested in...
Psychopharm Cmte. Crafts Statement To Avoid Public Misunderstanding
FDA's Psychopharmacologic Drugs Advisory Committee crafted a statement on the need for long-term efficacy data for psychiatric drugs in order to avoid public misperception of the outcome of its Oct. 25 meeting
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011